NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









March Biosciences

March Biosciences

Private
Houston, TexasHealthcare & Life Scienceshttps://march.bio/

Last Round

Series A

Oct 23, 2024

Est. Valuation

$47M

Total Funding Raised

$45.88M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

March Biosciences is a biotechnology company that develops CAR-T cell therapies for the treatment of hematological cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T cell therapycell therapyT-cell lymphomaregenerative medicineRMATclinical-stage biotechregenerative medicine advanced therapyhematologic malignanciesCD5-positive lymphomacancer immunotherapybiopharma R&Dclinical trialsoncology pipelinecell engineeringbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

March Biosciences Comps

Public and private peers based on sector, stage, and business model.

March Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

March Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 23, 2024
GrantSep 1, 2024
GrantNov 15, 2023
VC RoundNov 9, 2023
SeedJun 26, 2023

Key People

Founding team and executive leadership

Sarah Hein

Cofounder CEO

Founding Team

Leah DiMascio

COO

Executive Team

March Biosciences Investors

Notable investors and investment history

March Biosciences investors
InvestorRounds
National Cancer InstituteGrant
NIH RADxGrant
4Bio CapitalSeries A
The University of Texas MD Anderson Cancer CenterVC Round, Series A
CANCER FUNDSeries A
Texas Medical Center Venture FundSeed
Cancer Focus FundSeries A, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 24, 2026

    Grew 19% QoQ, from 21 to 25 employees.

  • Sep 1, 2024

    Secured $1.1M from National Cancer Institute and NIH RADx.

March Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

March Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about March Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersHouston, Texas
Employee Range24
Year Founded2022
Last FundingOct 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.